Michael Okunewitch
Stock Analyst at Maxim Group
(0.60)
# 3,755
Out of 4,728 analysts
20
Total ratings
21.05%
Success rate
-10.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $0.55 | +445.45% | 1 | Jan 10, 2025 | |
| CTOR Citius Oncology | Initiates: Buy | $3 | $1.06 | +183.02% | 1 | Nov 27, 2024 | |
| OCGN Ocugen | Initiates: Buy | $4 | $0.73 | +445.48% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $1.88 | +538.30% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.81 | +231.49% | 2 | Aug 27, 2024 | |
| CMMB Chemomab Therapeutics | Initiates: Buy | $4 | $1.90 | +110.53% | 1 | May 13, 2024 | |
| LEXX Lexaria Bioscience | Maintains: Buy | $3 → $12 | $1.93 | +521.76% | 2 | Mar 5, 2024 | |
| ACRV Acrivon Therapeutics | Initiates: Buy | $24 | $5.56 | +331.65% | 1 | Oct 5, 2023 | |
| ANEB Anebulo Pharmaceuticals | Initiates: Buy | $6 | $1.60 | +276.06% | 1 | Sep 21, 2023 | |
| KPRX Kiora Pharmaceuticals | Maintains: Buy | $108 → $18 | $3.21 | +460.75% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $1.13 | +19,811.50% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $19.02 | +31.44% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.82 | +230.58% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.34 | +1,068.22% | 1 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.33 | +1,779.70% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $3.56 | +2,708.99% | 1 | Nov 30, 2021 |
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.55
Upside: +445.45%
Citius Oncology
Nov 27, 2024
Initiates: Buy
Price Target: $3
Current: $1.06
Upside: +183.02%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $0.73
Upside: +445.48%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $1.88
Upside: +538.30%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.81
Upside: +231.49%
Chemomab Therapeutics
May 13, 2024
Initiates: Buy
Price Target: $4
Current: $1.90
Upside: +110.53%
Lexaria Bioscience
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $1.93
Upside: +521.76%
Acrivon Therapeutics
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $5.56
Upside: +331.65%
Anebulo Pharmaceuticals
Sep 21, 2023
Initiates: Buy
Price Target: $6
Current: $1.60
Upside: +276.06%
Kiora Pharmaceuticals
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $3.21
Upside: +460.75%
Apr 12, 2023
Initiates: Buy
Price Target: $225
Current: $1.13
Upside: +19,811.50%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $19.02
Upside: +31.44%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.82
Upside: +230.58%
Mar 24, 2022
Initiates: Buy
Price Target: $4
Current: $0.34
Upside: +1,068.22%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $1.33
Upside: +1,779.70%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $3.56
Upside: +2,708.99%